Medical School · Year 3 · Internal Medicine · includes a quiz and discussion video

Seminar 02: Approach to Dyspnea

Year 3: Internal Medicine Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Develop a systematic approach to evaluating dyspnea
2. Differentiate pulmonary from cardiac causes of dyspnea
3. Identify clinical features requiring urgent intervention
4. Describe the diagnostic workup for acute and chronic dyspnea
5. Apply appropriate management strategies based on etiology
6. Recognize dyspnea presentations in special populations

I. Overview of Dyspnea

Dyspnea represents a subjective sensation of breathing discomfort that encompasses various qualitative experiences including air hunger, chest tightness, and increased effort of breathing. The perception of dyspnea arises from complex neural processing involving integration of signals from chemoreceptors detecting hypoxia and hypercapnia, mechanoreceptors in the lungs and chest wall, and central respiratory centers in the brainstem. The fundamental pathophysiology involves a mismatch between ventilatory demand and the capacity of the respiratory system to meet that demand, creating conscious awareness of respiratory effort. Importantly, the severity of dyspnea does not always correlate with objective measures of respiratory function, as perception varies significantly among individuals based on psychological factors, prior experiences, and central processing differences.

The mechanisms underlying dyspnea can be classified into distinct pathophysiologic categories that guide diagnostic evaluation. Increased respiratory drive occurs when chemoreceptors sense hypoxia, hypercapnia, or metabolic acidosis, prompting augmented ventilatory effort that patients perceive as air hunger. Increased work of breathing results from airway obstruction in conditions like asthma and chronic obstructive pulmonary disease, or from decreased lung compliance in pulmonary fibrosis and pulmonary edema. Decreased ventilatory capacity occurs with neuromuscular weakness affecting the diaphragm and accessory muscles, or with deconditioning from prolonged immobility. Psychological factors including anxiety and panic disorder can produce dyspnea through hyperventilation in the absence of underlying cardiopulmonary disease.

Temporal classification of dyspnea provides crucial diagnostic information based on the time course of symptom development. Acute dyspnea developing over minutes suggests immediately life-threatening conditions including pulmonary embolism, pneumothorax, acute asthma exacerbation, and anaphylaxis requiring emergent evaluation and treatment. Subacute dyspnea progressing over hours to days commonly results from heart failure exacerbation, pneumonia, or chronic obstructive pulmonary disease exacerbation. Chronic dyspnea developing over weeks to months occurs with progressive conditions including chronic obstructive pulmonary disease, interstitial lung disease, and slowly progressive heart failure. Episodic dyspnea with symptom-free intervals characterizes asthma triggered by allergens or exercise, gastroesophageal reflux-related bronchospasm, and anxiety-induced hyperventilation.

Life-threatening causes of dyspnea demand immediate recognition and intervention to prevent respiratory failure and death. Pulmonary embolism presents with acute dyspnea accompanied by pleuritic chest pain, with risk factors including immobility, malignancy, and recent surgery. Tension pneumothorax causes sudden severe dyspnea with absent breath sounds and tracheal deviation away from the affected side, requiring immediate needle decompression. Severe asthma or chronic obstructive pulmonary disease exacerbation manifests with wheezing, accessory muscle use, and difficulty speaking in full sentences. Acute pulmonary edema from decompensated heart failure presents with orthopnea, jugular venous distension, and bilateral crackles on lung examination. Anaphylaxis produces dyspnea through bronchospasm and upper airway edema, accompanied by urticaria, angioedema, and hypotension. Upper airway obstruction from foreign body or angioedema causes stridor and respiratory distress requiring immediate airway management.

<image>Panel A: Neuroanatomical diagram illustrating the respiratory control centers, chemoreceptor inputs, and mechanoreceptor feedback loops that generate dyspnea perception. Panel B: Temporal classification flowchart showing acute, subacute, chronic, and episodic dyspnea patterns with associated etiologies at each time course. Panel C: Clinical photographs demonstrating signs of respiratory distress including tripod positioning, accessory muscle use, and nasal flaring. Panel D: Emergency algorithm for life-threatening causes of dyspnea with immediate interventions for each condition.</image>

II. History Taking

Characterization of dyspnea requires detailed questioning about onset, duration, triggers, and associated symptoms to narrow the differential diagnosis. Sudden onset suggests acute conditions including pulmonary embolism, pneumothorax, or cardiac arrhythmia, while gradual onset over months indicates chronic cardiopulmonary disease. Duration helps distinguish acute exacerbations of chronic conditions from new diagnoses requiring comprehensive evaluation. Triggers provide diagnostic clues, with exertional dyspnea suggesting cardiac limitation, allergen exposure indicating asthma, and positional symptoms pointing toward heart failure or diaphragmatic weakness. Associated symptoms including chest pain suggest pulmonary embolism, pericarditis, or coronary disease, while fever indicates infectious etiology. The clinician must determine whether symptoms occur at rest, during minimal activity, or only with significant exertion.

Functional assessment using standardized scales quantifies dyspnea severity and tracks response to treatment. The Modified Medical Research Council dyspnea scale grades symptoms from zero to four, with grade one indicating dyspnea only with strenuous exercise, grade two with walking uphill or hurrying, grade three when walking slower than peers on flat ground, grade four when stopping after one hundred meters of walking, and grade five when too breathless to leave the house or dress. This grading system has prognostic value in chronic obstructive pulmonary disease and helps guide therapy intensity. Asking patients to describe their typical daily activities and limitations provides practical functional assessment. Exercise tolerance measured in blocks walked or flights of stairs climbed offers reproducible assessment over time.

Associated symptoms help localize the pathology and guide diagnostic evaluation. Chest pain accompanying dyspnea raises concern for acute coronary syndrome, pulmonary embolism, pneumonia, or pericarditis depending on pain characteristics. Orthopnea, the need to sleep propped up on pillows, and paroxysmal nocturnal dyspnea, awakening with breathlessness hours after lying down, strongly suggest heart failure with elevated filling pressures. Cough may indicate infection, asthma, heart failure with pulmonary congestion, or interstitial lung disease. Wheezing suggests bronchospasm from asthma, chronic obstructive pulmonary disease, or cardiac asthma from pulmonary edema. Fever points toward infectious etiology requiring antimicrobial therapy. Leg swelling suggests right heart failure or deep vein thrombosis as a source for pulmonary embolism. Unintentional weight loss raises concern for malignancy or advanced chronic lung disease with cachexia.

Risk factor assessment identifies predisposing conditions and guides diagnostic testing. Cardiac risk factors including hypertension, coronary artery disease, prior myocardial infarction, and valvular disease increase likelihood of heart failure as the cause of dyspnea. Pulmonary risk factors include smoking history quantified in pack-years, occupational exposures to dusts and fumes, and prior diagnosis of asthma or chronic obstructive pulmonary disease. Venous thromboembolism risk factors following Virchow's triad include immobility, recent surgery, malignancy, estrogen use, and prior venous thromboembolism. Other contributing factors include anemia reducing oxygen carrying capacity, obesity causing restrictive physiology and deconditioning, and neuromuscular diseases affecting respiratory muscle strength.

<image>Panel A: Interview framework diagram showing systematic questioning approach for dyspnea characterization with branching decision points. Panel B: Modified Medical Research Council dyspnea scale visual representation with functional capacity descriptions at each grade level. Panel C: Body diagram illustrating associated symptoms and their localization value including leg edema, chest pain, and orthopnea. Panel D: Risk factor checklist organized by cardiac, pulmonary, and thrombotic categories with corresponding diagnostic implications.</image>

III. Physical Examination

General assessment provides immediate information about the severity of respiratory distress and need for urgent intervention. Signs of respiratory distress include accessory muscle use with visible sternocleidomastoid and intercostal muscle contraction, tripod positioning with the patient leaning forward on extended arms to optimize diaphragmatic mechanics, and nasal flaring indicating increased respiratory effort. Central cyanosis with blue discoloration of the lips and tongue indicates severe hypoxemia requiring immediate supplemental oxygen. Diaphoresis accompanies respiratory distress and also suggests acute coronary syndrome as a cause of dyspnea. Altered mental status with confusion or somnolence indicates hypercapnia or severe hypoxia requiring immediate intervention. Body habitus assessment identifies obesity contributing to restrictive physiology and deconditioning, or cachexia suggesting advanced chronic disease or malignancy.

Vital sign assessment quantifies the severity of respiratory compromise and guides treatment intensity. Tachypnea with respiratory rate above twenty breaths per minute occurs with many causes of dyspnea and correlates with disease severity. Pulse oximetry measuring oxygen saturation below ninety percent indicates significant hypoxia requiring supplemental oxygen and aggressive evaluation. Tachycardia may reflect compensation for hypoxia, pain, fever, or primary cardiac conditions including heart failure, arrhythmia, and pulmonary embolism. Hypotension suggests shock from massive pulmonary embolism, tension pneumothorax, or cardiac tamponade requiring immediate resuscitation. Fever indicates infection as a likely contributing factor. Pulsus paradoxus, an exaggerated decrease in systolic blood pressure during inspiration greater than ten millimeters of mercury, occurs with severe asthma, cardiac tamponade, and chronic obstructive pulmonary disease exacerbation.

Pulmonary examination findings localize disease and suggest specific etiologies. Wheezing, a high-pitched continuous sound heard during expiration, indicates airway narrowing from asthma, chronic obstructive pulmonary disease, or bronchospasm from heart failure termed cardiac asthma. Crackles or rales, discontinuous sounds heard during inspiration, suggest fluid in alveoli from pulmonary edema or fibrosis, or consolidation from pneumonia. Decreased breath sounds may indicate chronic obstructive pulmonary disease with hyperinflation, pleural effusion preventing sound transmission, or pneumothorax with absent air movement. Rhonchi, low-pitched continuous sounds from secretions in larger airways, occur with bronchitis and retained secretions. Stridor, a high-pitched inspiratory sound, indicates upper airway obstruction requiring immediate attention. Dullness to percussion suggests pleural effusion or consolidation, while hyperresonance indicates pneumothorax or severe emphysema.

Cardiovascular examination findings identify cardiac causes of dyspnea and guide management. Jugular venous distension indicates elevated right atrial pressure from right heart failure, tamponade, or massive pulmonary embolism with right ventricular strain. An S3 gallop, a low-pitched sound in early diastole, indicates volume overload and left ventricular dysfunction consistent with decompensated heart failure. New or changing heart murmurs may indicate valvular disease causing heart failure or endocarditis with septic emboli to the lungs. Peripheral edema with bilateral pitting ankle swelling suggests right heart failure, while asymmetric unilateral leg swelling raises concern for deep vein thrombosis as a source for pulmonary embolism. Hepatojugular reflux, sustained jugular venous distension with abdominal pressure, confirms elevated right-sided filling pressures in heart failure.

<image>Panel A: Clinical photographs demonstrating accessory muscle use, tripod positioning, and pursed lip breathing in patients with respiratory distress. Panel B: Auscultation landmarks diagram with audio waveform representations of normal breath sounds, wheezes, crackles, and stridor. Panel C: Jugular venous pressure assessment technique with patient positioning and waveform interpretation. Panel D: Algorithm integrating physical examination findings with likely diagnoses and recommended diagnostic testing.</image>

IV. Cardiac Causes

Heart failure represents one of the most common causes of dyspnea, with symptoms arising from pulmonary congestion and reduced cardiac output. Left-sided heart failure causes pulmonary venous congestion with transudation of fluid into the interstitium and alveoli, manifesting as dyspnea, orthopnea, and paroxysmal nocturnal dyspnea. Right-sided heart failure produces systemic venous congestion with peripheral edema, jugular venous distension, and hepatomegaly, often occurring secondary to left heart failure or primary pulmonary disease. Biventricular failure combines features of both with severe functional limitation. Classification by ejection fraction distinguishes heart failure with reduced ejection fraction below forty percent, indicating systolic dysfunction, from heart failure with preserved ejection fraction above fifty percent, indicating diastolic dysfunction with impaired ventricular relaxation. B-type natriuretic peptide measurement helps differentiate cardiac from pulmonary causes of dyspnea, with elevated levels strongly supporting heart failure.

The specific symptoms of heart failure reflect the underlying pathophysiology of congestion and hypoperfusion. Orthopnea occurs because the supine position increases venous return and preload, exacerbating pulmonary congestion in patients with elevated filling pressures. Patients quantify orthopnea by the number of pillows needed to sleep comfortably. Paroxysmal nocturnal dyspnea develops hours after assuming the supine position as interstitial fluid gradually redistributes to the pulmonary vasculature, awakening patients with severe breathlessness relieved by sitting upright. Bendopnea describes dyspnea occurring within thirty seconds of bending forward, reflecting acutely elevated filling pressures, and correlates with more severe hemodynamic derangement. Exertional dyspnea results from inability to augment cardiac output appropriately to meet increased metabolic demands during physical activity.

Acute coronary syndrome may present with dyspnea as an anginal equivalent rather than typical chest pain, particularly in diabetic patients with autonomic neuropathy, elderly patients, and women. The dyspnea results from acute left ventricular dysfunction secondary to myocardial ischemia reducing contractility and compliance. This presentation is considered high-risk because the absence of typical chest pain may lead to delayed diagnosis and treatment. Electrocardiogram and troponin measurement should be obtained in patients with unexplained dyspnea, particularly those with cardiac risk factors. Emergency coronary intervention may be required for patients with evidence of acute coronary syndrome presenting primarily with dyspnea.

Valvular heart disease produces dyspnea through various mechanisms depending on the specific lesion. Aortic stenosis causes exertional dyspnea due to fixed cardiac output that cannot increase appropriately with activity, often accompanied by angina and syncope completing the classic triad. Mitral stenosis, most commonly from rheumatic heart disease, produces dyspnea through elevated left atrial pressure transmitted to the pulmonary veins, and may cause hemoptysis and atrial fibrillation. Mitral regurgitation causes pulmonary congestion when severe, with acute mitral regurgitation from papillary muscle rupture presenting as flash pulmonary edema. Echocardiography establishes the diagnosis of valvular disease and quantifies severity to guide decisions regarding surgical or percutaneous intervention.

<image>Panel A: Pathophysiology diagram of left heart failure showing elevated left atrial pressure, pulmonary venous congestion, and resulting pulmonary edema formation. Panel B: Comparison of heart failure with reduced versus preserved ejection fraction including echocardiographic images and hemodynamic tracings. Panel C: Clinical timeline illustration of orthopnea and paroxysmal nocturnal dyspnea development after assuming supine position. Panel D: Valvular heart disease comparison showing hemodynamic effects and characteristic murmur findings for aortic stenosis, mitral stenosis, and mitral regurgitation.</image>

V. Pulmonary Causes

Obstructive lung diseases including asthma and chronic obstructive pulmonary disease cause dyspnea through airflow limitation, air trapping, and dynamic hyperinflation. Asthma presents with episodic wheezing, cough, and dyspnea triggered by allergens, exercise, respiratory infections, or cold air, with characteristic reversibility demonstrated on spirometry. Chronic obstructive pulmonary disease develops in patients with significant smoking history, presenting with progressive dyspnea, chronic cough, and sputum production, with airflow obstruction that is not fully reversible. Bronchiectasis causes chronic cough with copious sputum production, recurrent infections, and progressive bronchial damage. Spirometric diagnosis of obstructive disease demonstrates reduced ratio of forced expiratory volume in one second to forced vital capacity below zero point seven, with the degree of reduction in forced expiratory volume in one second correlating with disease severity and prognosis.

Restrictive lung diseases cause dyspnea through reduced lung volumes and impaired gas exchange. Interstitial lung diseases including idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, and connective tissue disease-associated lung disease present with progressive exertional dyspnea and nonproductive cough. Physical examination reveals fine inspiratory crackles, and clubbing may develop with advanced disease. Pulmonary fibrosis shows characteristic honeycombing on high-resolution computed tomography, predominantly in the lower lobes and periphery. Sarcoidosis causes hilar lymphadenopathy and pulmonary infiltrates with multisystem manifestations. Spirometry in restrictive disease demonstrates reduced total lung capacity and forced vital capacity with preserved or elevated ratio of forced expiratory volume in one second to forced vital capacity. Diffusing capacity for carbon monoxide is reduced, indicating impaired gas exchange across the thickened alveolar-capillary membrane.

Pulmonary vascular diseases cause dyspnea through impaired gas exchange and right ventricular strain. Pulmonary embolism presents with acute dyspnea, often accompanied by pleuritic chest pain, with risk factors including immobility, surgery, malignancy, and hypercoagulable states. Diagnosis requires assessment of pretest probability using clinical prediction rules followed by D-dimer testing or computed tomographic pulmonary angiography. Pulmonary hypertension causes progressive exertional dyspnea with eventual right heart failure, presenting with jugular venous distension, peripheral edema, and loud pulmonic component of the second heart sound. Diagnosis requires echocardiography demonstrating elevated pulmonary artery pressures, with right heart catheterization providing definitive hemodynamic assessment. Causes include idiopathic pulmonary arterial hypertension, left heart disease, chronic lung disease, and chronic thromboembolic disease.

Pleural diseases cause dyspnea by restricting lung expansion and impairing ventilation. Pleural effusion produces dyspnea proportional to the volume of fluid accumulation, with physical examination revealing dullness to percussion and decreased breath sounds over the affected hemithorax. Large effusions may cause mediastinal shift with tracheal deviation toward the contralateral side. Diagnostic thoracentesis determines whether the effusion is transudative from heart failure, nephrotic syndrome, or cirrhosis, or exudative from infection, malignancy, or inflammatory conditions using Light's criteria. Pneumothorax causes sudden dyspnea with decreased breath sounds and hyperresonance on the affected side. Tension pneumothorax represents a medical emergency with hemodynamic collapse requiring immediate needle decompression before radiographic confirmation.

<image>Panel A: Spirometry flow-volume loops comparing normal, obstructive, and restrictive patterns with corresponding disease examples. Panel B: High-resolution CT chest images contrasting emphysema, interstitial lung disease with honeycombing, and normal parenchyma. Panel C: CT pulmonary angiography demonstrating pulmonary embolism with filling defects in pulmonary arteries and right ventricular strain. Panel D: Chest radiograph and ultrasound images of pleural effusion with anatomical landmarks for thoracentesis.</image>

VI. Other Causes

Anemia causes dyspnea by reducing oxygen-carrying capacity of the blood, requiring increased cardiac output to maintain tissue oxygen delivery. Patients with anemia experience exertional dyspnea as the cardiovascular system cannot adequately compensate for reduced hemoglobin during increased metabolic demand. Physical examination may reveal pallor of the conjunctivae, nail beds, and palmar creases, along with tachycardia at rest indicating compensatory increased cardiac output. The severity of dyspnea correlates with the degree of anemia and the rapidity of hemoglobin decline, with acute blood loss causing more symptoms than chronic anemia at the same hemoglobin level due to lack of physiologic adaptation. Complete blood count establishes the diagnosis, with further evaluation to determine the underlying cause including iron deficiency, vitamin B12 or folate deficiency, hemolysis, or bone marrow failure.

Neuromuscular diseases affecting the respiratory muscles cause dyspnea through ventilatory pump failure. Amyotrophic lateral sclerosis causes progressive weakness of the diaphragm and accessory muscles, with dyspnea often developing insidiously and becoming the limiting symptom. Myasthenia gravis produces fatigable weakness that may affect respiratory muscles, causing respiratory crisis in severe exacerbations. Guillain-Barre syndrome causes ascending weakness that can rapidly progress to respiratory failure requiring mechanical ventilation. Assessment of respiratory muscle strength includes measurement of maximal inspiratory pressure and vital capacity, with values below threshold indicating need for ventilatory support. Diaphragmatic weakness causes orthopnea due to loss of gravitational assistance in the upright position and reliance on accessory muscles.

Metabolic and endocrine conditions cause dyspnea through various mechanisms. Metabolic acidosis from diabetic ketoacidosis, lactic acidosis, or renal failure stimulates respiratory drive through chemoreceptor activation, producing Kussmaul breathing with deep, rapid respirations as respiratory compensation for the acidemia. Thyroid disease affects respiratory function, with hyperthyroidism causing dyspnea through increased metabolic demand and tachycardia, while severe hypothyroidism may cause hypoventilation, pleural effusions, and respiratory muscle weakness. Obesity contributes to dyspnea through restrictive lung physiology from chest wall and abdominal mass, deconditioning, and obesity hypoventilation syndrome in severe cases. Pregnancy causes physiologic dyspnea in up to seventy percent of women due to increased minute ventilation and elevated diaphragm, though pathologic causes must still be considered.

Psychogenic dyspnea results from anxiety and panic disorder in the absence of underlying cardiopulmonary disease. Patients experience air hunger and often hyperventilate, which causes hypocapnia leading to paresthesias around the mouth and in the extremities, lightheadedness, and even tetany from respiratory alkalosis. Sighing dyspnea with frequent deep breaths interrupting normal respiration pattern suggests psychogenic etiology. Physical examination and diagnostic testing are normal between episodes, and symptoms often occur in specific anxiety-provoking situations. However, psychogenic dyspnea remains a diagnosis of exclusion, and organic causes must be thoroughly ruled out before attributing symptoms to anxiety. Treatment involves reassurance, cognitive behavioral therapy, and management of underlying anxiety disorder.

<image>Panel A: Oxygen delivery equation diagram showing the relationship between hemoglobin concentration, oxygen saturation, and cardiac output in determining tissue oxygenation. Panel B: Pulmonary function testing in neuromuscular disease demonstrating reduced vital capacity and maximal inspiratory pressure with clinical correlation. Panel C: Arterial blood gas interpretation in metabolic acidosis showing primary disturbance and respiratory compensation with Kussmaul breathing pattern. Panel D: Hyperventilation syndrome physiology illustrating hypocapnia effects including cerebral vasoconstriction, paresthesias, and tetany with typical patient presentation.</image>

VII. Diagnostic Workup

Initial diagnostic tests establish baseline cardiopulmonary status and identify common causes of dyspnea. Pulse oximetry provides immediate assessment of oxygenation, with values below ninety percent indicating significant hypoxemia requiring supplemental oxygen. Chest radiography evaluates pulmonary parenchyma for infiltrates, masses, and interstitial changes, heart size for cardiomegaly suggesting heart failure, and pleural spaces for effusions or pneumothorax. Electrocardiogram identifies arrhythmias, ischemic changes, or right heart strain patterns suggesting pulmonary embolism. Complete blood count diagnoses anemia and may reveal leukocytosis suggesting infection. Basic metabolic panel identifies metabolic acidosis, renal dysfunction, and electrolyte abnormalities affecting respiratory muscle function.

Cardiac workup helps distinguish cardiac from pulmonary causes of dyspnea using biomarkers and imaging. Brain natriuretic peptide and its precursor N-terminal pro-BNP are released by ventricular myocytes in response to wall stretch, with levels below one hundred picograms per milliliter for BNP making heart failure unlikely and levels above four hundred strongly supporting the diagnosis. Intermediate values require clinical correlation considering factors that cause false elevation including renal failure, pulmonary embolism, and atrial fibrillation, and false reduction including obesity. Troponin measurement rules out acute coronary syndrome as a cause of dyspnea. Echocardiography provides definitive assessment of cardiac structure and function, evaluating left ventricular ejection fraction, diastolic function, valvular abnormalities, and right ventricular size and function suggesting pulmonary hypertension.

Pulmonary workup establishes the cause and severity of lung disease contributing to dyspnea. Arterial blood gas analysis quantifies the degree of hypoxemia and identifies hypercapnia indicating ventilatory failure, while providing acid-base status to diagnose metabolic acidosis causing compensatory hyperventilation. Spirometry differentiates obstructive from restrictive patterns and quantifies severity, with post-bronchodilator testing assessing reversibility characteristic of asthma. D-dimer testing excludes pulmonary embolism in patients with low pretest probability, while computed tomographic pulmonary angiography provides definitive diagnosis in those with elevated probability or positive D-dimer. High-resolution computed tomography characterizes interstitial lung disease, bronchiectasis, and emphysema with greater detail than chest radiography.

Brain natriuretic peptide interpretation requires understanding of the clinical context and potential confounders. Values below one hundred picograms per milliliter have high negative predictive value for excluding heart failure, while values above four hundred strongly support the diagnosis in patients with compatible clinical presentation. The intermediate range between one hundred and four hundred requires consideration of clinical factors and additional testing. False elevations occur with renal failure due to decreased clearance, pulmonary embolism causing right ventricular strain, atrial fibrillation, and older age. Obesity paradoxically causes false reduction due to natriuretic peptide clearance by adipose tissue. Trending values over time provides useful information about treatment response, with reduction correlating with clinical improvement.

<image>Panel A: Diagnostic algorithm for dyspnea workup integrating history, physical examination, and sequential testing based on clinical probability. Panel B: Brain natriuretic peptide interpretation chart with thresholds for ruling out and ruling in heart failure, including confounding factors. Panel C: Spirometry interpretation guide with flow-volume loops demonstrating obstructive and restrictive patterns with severity grading. Panel D: Chest imaging comparison showing radiograph and CT findings in common causes of dyspnea including heart failure, pneumonia, COPD, and interstitial lung disease.</image>

VIII. Acute Dyspnea Management

Initial stabilization of the acutely dyspneic patient prioritizes airway, breathing, and circulation while diagnostic evaluation proceeds. Supplemental oxygen should be administered to maintain oxygen saturation above ninety-two percent, using nasal cannula for mild hypoxemia and non-rebreather mask for severe hypoxemia. Patient positioning upright reduces preload and pulmonary congestion in heart failure while optimizing diaphragmatic mechanics. Intravenous access allows medication administration and fluid resuscitation if needed. Continuous monitoring including pulse oximetry, cardiac telemetry, and blood pressure assessment enables detection of deterioration. The threshold for intubation should be assessed early, with impending respiratory failure identified by progressive tachypnea, accessory muscle use, inability to speak, and altered mental status.

Heart failure exacerbation management targets fluid removal and optimization of hemodynamics. Intravenous loop diuretics such as furosemide provide rapid diuresis to reduce pulmonary congestion, with dosing typically starting at one to two times the patient's home oral dose given intravenously. Nitroglycerin reduces preload through venodilation and is particularly useful in hypertensive heart failure with flash pulmonary edema. Non-invasive positive pressure ventilation with bilevel positive airway pressure or continuous positive airway pressure reduces work of breathing, improves oxygenation, and decreases preload and afterload, often avoiding the need for intubation. Morphine has been used historically to reduce preload and anxiety but should be used cautiously due to potential respiratory depression. Identification and treatment of precipitating factors including dietary indiscretion, medication non-adherence, infection, arrhythmia, or ischemia is essential.

Asthma and chronic obstructive pulmonary disease exacerbation management focuses on bronchodilation, anti-inflammatory therapy, and treatment of triggers. Short-acting bronchodilators including albuterol and ipratropium are administered via nebulizer or metered-dose inhaler with spacer, with continuous nebulization for severe exacerbations. Systemic corticosteroids reduce airway inflammation and should be administered early, with oral prednisone equivalent to intravenous methylprednisolone for most patients. Intravenous magnesium sulfate provides additional bronchodilation in severe asthma unresponsive to initial therapy. Non-invasive positive pressure ventilation reduces work of breathing and improves gas exchange in chronic obstructive pulmonary disease exacerbation with hypercapnic respiratory failure. Antibiotics are indicated for chronic obstructive pulmonary disease exacerbation when bacterial infection is suspected based on purulent sputum or fever. Intubation is reserved for patients failing non-invasive ventilation or with severe distress.

Pulmonary embolism management depends on hemodynamic severity and bleeding risk. Stable patients receive anticoagulation with direct oral anticoagulants preferred for most, using apixaban or rivaroxaban which do not require parenteral bridging. Submassive pulmonary embolism with right ventricular dysfunction or elevated biomarkers requires close monitoring with consideration of thrombolysis if clinical deterioration occurs. Massive pulmonary embolism with hemodynamic instability warrants systemic thrombolysis with alteplase or surgical or catheter-directed embolectomy depending on institutional capabilities and contraindications. Anticoagulation should not be delayed for confirmatory imaging in patients with high clinical probability and hemodynamic compromise. Inferior vena cava filter placement is reserved for patients with absolute contraindication to anticoagulation.

<image>Panel A: Acute dyspnea stabilization protocol with oxygen delivery devices, monitoring parameters, and intubation criteria. Panel B: Heart failure exacerbation treatment algorithm showing diuretic dosing, vasodilator use, and non-invasive ventilation indications. Panel C: Asthma and COPD exacerbation severity assessment with corresponding treatment escalation from bronchodilators to mechanical ventilation. Panel D: Pulmonary embolism risk stratification and treatment algorithm based on hemodynamic status and right ventricular function.</image>

IX. Chronic Dyspnea Evaluation

Stepwise evaluation of chronic dyspnea proceeds from basic assessment to advanced testing based on clinical findings. Initial evaluation includes thorough history and physical examination, chest radiography to identify obvious cardiopulmonary abnormalities, and spirometry to characterize obstructive or restrictive physiology. If cardiac disease is suspected based on risk factors or examination findings, echocardiography assesses ventricular function and valvular abnormalities. When pulmonary disease is suspected, computed tomography of the chest provides detailed parenchymal evaluation for interstitial lung disease, bronchiectasis, or occult malignancy. Cardiopulmonary exercise testing is valuable when the diagnosis remains unclear after initial workup, objectively quantifying functional capacity and distinguishing cardiac from pulmonary limitation. Psychiatric evaluation is considered when workup is negative and anxiety or panic disorder is suspected.

Pulmonary function testing provides objective assessment of lung mechanics and gas exchange. Spirometry measures forced vital capacity and forced expiratory volume in one second, with the ratio distinguishing obstructive from restrictive patterns. Bronchodilator response testing identifies reversible obstruction characteristic of asthma. Lung volume measurement by plethysmography confirms restriction when total lung capacity is reduced. Diffusing capacity for carbon monoxide assesses gas exchange across the alveolar-capillary membrane, with reduction indicating interstitial lung disease, emphysema, pulmonary vascular disease, or anemia. Flow-volume loop analysis identifies upper airway obstruction with characteristic flattening of the inspiratory or expiratory limb.

Cardiopulmonary exercise testing provides comprehensive assessment of exercise capacity and physiologic limitation. Patients exercise on a treadmill or cycle ergometer with continuous monitoring of ventilation, gas exchange, and cardiac parameters. Peak oxygen consumption quantifies maximum aerobic capacity and correlates with functional status and prognosis. Anaerobic threshold identifies the point at which lactate accumulation begins, with early threshold suggesting cardiac limitation or deconditioning. Oxygen pulse, calculated as oxygen consumption divided by heart rate, serves as a surrogate for stroke volume. Ventilatory efficiency measured by the ratio of minute ventilation to carbon dioxide production increases with pulmonary vascular disease and heart failure. The pattern of limitation distinguishes cardiac, pulmonary, and deconditioning causes of dyspnea when other testing is inconclusive.

Chronic obstructive pulmonary disease management combines pharmacologic and non-pharmacologic interventions tailored to symptom severity and exacerbation risk. Smoking cessation provides the greatest mortality benefit and slows disease progression, with pharmacotherapy including nicotine replacement, varenicline, and bupropion improving quit rates. Bronchodilators including long-acting muscarinic antagonists and long-acting beta-agonists reduce symptoms and exacerbations. Inhaled corticosteroids are added for patients with elevated eosinophils or frequent exacerbations. Pulmonary rehabilitation combining exercise training, education, and psychosocial support improves functional capacity and quality of life. Long-term oxygen therapy for patients with chronic hypoxemia improves survival. Vaccinations against influenza, pneumococcus, and COVID-19 prevent infectious exacerbations.

<image>Panel A: Stepwise diagnostic algorithm for chronic dyspnea evaluation proceeding from basic to advanced testing based on clinical findings. Panel B: Pulmonary function test interpretation flowchart with spirometry, lung volumes, and diffusing capacity findings in common conditions. Panel C: Cardiopulmonary exercise testing report with normal and abnormal patterns demonstrating cardiac limitation, pulmonary limitation, and deconditioning. Panel D: GOLD classification for COPD management showing symptom and exacerbation risk assessment with corresponding treatment recommendations.</image>

X. Special Populations

Pregnant patients commonly experience physiologic dyspnea due to hormonal effects increasing minute ventilation and mechanical effects of the gravid uterus elevating the diaphragm. Up to seventy percent of pregnant women report dyspnea, typically beginning in the first or second trimester and stabilizing or improving near term. However, pathologic causes of dyspnea must still be considered, with pulmonary embolism risk significantly elevated during pregnancy and the postpartum period due to hypercoagulability and venous stasis. Peripartum cardiomyopathy presents with heart failure in the last month of pregnancy or within five months postpartum, requiring prompt recognition and treatment. D-dimer is physiologically elevated during pregnancy, reducing its utility for excluding pulmonary embolism, and imaging with CT pulmonary angiography or ventilation-perfusion scanning may be necessary. Treatment of pulmonary embolism during pregnancy requires low-molecular-weight heparin, as direct oral anticoagulants and warfarin are contraindicated.

Elderly patients with dyspnea often have multiple contributing factors requiring comprehensive evaluation. Age-related changes in pulmonary mechanics, decreased respiratory muscle strength, and reduced cardiovascular reserve lower the threshold for dyspnea. Atypical presentations are common, with dyspnea as the primary symptom of myocardial infarction, pneumonia, or pulmonary embolism rather than classic findings. Deconditioning from chronic illness and reduced activity significantly contributes to exercise intolerance. Polypharmacy introduces the possibility of drug-induced dyspnea from beta-blockers, non-dihydropyridine calcium channel blockers, or medications causing pulmonary toxicity. Frailty assessment helps guide treatment intensity and prognosis. Multidisciplinary evaluation addressing cardiac, pulmonary, functional, and psychosocial factors optimizes management in this population.

Immunocompromised patients are susceptible to opportunistic infections causing dyspnea that require specific diagnostic approaches. Pneumocystis jirovecii pneumonia occurs in HIV patients with CD4 counts below two hundred, presenting with progressive dyspnea, dry cough, and diffuse interstitial infiltrates, diagnosed by induced sputum or bronchoalveolar lavage with special stains. Fungal infections including aspergillosis in severely neutropenic patients and endemic mycoses in transplant recipients require tissue diagnosis and antifungal therapy. Cytomegalovirus pneumonitis affects solid organ and hematopoietic stem cell transplant recipients on immunosuppression. Drug toxicity from chemotherapy and immunotherapy can cause pneumonitis requiring high-dose corticosteroids. Broad diagnostic evaluation including bronchoscopy with lavage and biopsy may be necessary to identify the causative pathology.

Dyspnea management in the palliative setting focuses on symptom relief when disease-modifying treatment is no longer appropriate or desired. Opioids reduce the sensation of dyspnea through central effects on respiratory centers and have demonstrated efficacy in multiple trials, with low-dose morphine commonly used. Facial cooling with a fan directed at the face activates the trigeminal nerve and reduces dyspnea perception. Supplemental oxygen provides benefit for hypoxemic patients but does not improve dyspnea in non-hypoxemic patients beyond placebo effect. Anxiolytics address the anxiety component that frequently accompanies dyspnea in advanced illness. Goals of care discussions should occur early to align treatment with patient values and preferences, addressing code status, ventilator use, and transition to comfort-focused care when appropriate.

<image>Panel A: Physiologic changes in pregnancy affecting respiratory system with normal versus concerning dyspnea characteristics for diagnostic consideration. Panel B: Comprehensive assessment framework for elderly patients with dyspnea addressing multifactorial etiology and polypharmacy review. Panel C: Opportunistic infection evaluation algorithm for immunocompromised patients with characteristic radiographic and clinical findings. Panel D: Palliative dyspnea management approach showing pharmacologic and non-pharmacologic interventions with goals of care discussion framework.</image>

Summary

• Dyspnea is a subjective sensation involving mismatch between ventilatory demand and capacity; assess severity with functional scales like MRC grade
• Life-threatening causes requiring immediate intervention include pulmonary embolism, tension pneumothorax, severe asthma or COPD exacerbation, and acute pulmonary edema
• Acute onset suggests PE, pneumothorax, or asthma; chronic onset suggests COPD, CHF, or interstitial lung disease
• History should characterize onset, triggers, and associated symptoms including orthopnea, chest pain, cough, and fever
• Physical examination assesses respiratory distress signs, lung findings, and cardiovascular findings including JVD and edema
• BNP helps differentiate cardiac from pulmonary causes, with values below 100 making heart failure unlikely
• Spirometry distinguishes obstructive from restrictive patterns; DLCO assesses gas exchange
• Heart failure treatment includes diuretics, vasodilators, and non-invasive positive pressure ventilation
• Asthma and COPD exacerbation treatment includes bronchodilators and systemic corticosteroids
• Pulmonary embolism treatment involves anticoagulation with thrombolysis for massive PE with hemodynamic instability

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown